Tigecycline among clinically significant multidrug resistant pathogens

<p><span><strong>Purpose</strong>:</span> Tigecycline, a glycylcycline antibiotic is a promising option for the treatment of single or multidrug-resistant pathogens. The aim of the study was to evaluate the in-vitro Tigecycline susceptibility of various pathogens from clinical samples received at tertiary care hospitals in South India. </p> <p><span><strong>Methods</strong>:</span> The analysis of specimens from patients admitted was carried out in this retrospective cross-sectional study. The identification and antimicrobial susceptibility testing were performed by semi-automated Vitek 2 systems and Kirby Bauer method. The pattern of data analysis was done by descriptive statistics.</p> <p><span><strong>Results</strong>:</span> Among 2,574 isolates, 812 isolates were gram-positive pathogens and 1762 isolates were gram-negative pathogens. Resistance to Tigecycline was more common among gram-negative pathogens (18.62%) in comparison to the gram-positive pathogens (0.49%). Among 740 Extended Spectrum Beta Lactamases (ESBL) producers such as <em>Klebsiella</em> species &amp; <em>E</em>. <em>coli</em>, 629 isolates were susceptible, and 93 isolates were resistant to the tigecycline. All the Methicillin Resistant <em>Staphylococcus</em> <em>aureus</em> (MRSA) isolates were susceptible to tigecycline. Tigecycline was found to be highly effective in vitro for elimination of infections caused by both gram-positive and gram-negative pathogens.</p> <p><span><strong>Conclusion</strong>:</span> Multidrug-resistant (MDR) pathogens like <em>Acinetobacter</em> species and <em>Klebsiella</em> species are highly susceptible to Tigecycline, and it remains one of the key drugs in monotherapy &amp; combination therapy. All MRSA were sensitive to tigeclycline. The use of combination therapy becomes crucial to prevent the development of Pan Drug resistance.</p>